• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

New agent proves its value in breast scintigraphy scans

Article

Breast scintigraphy with technetium-99m NC100692 is safe and effective and could be used to monitor cancer treatment response, according to a study published in the September issue of the Journal of Nuclear Medicine

Breast scintigraphy with technetium-99m NC100692 is safe and effective and could be used to monitor cancer treatment response, according to a study published in the September issue of the Journal of Nuclear Medicine.

Researchers at the Karolinska Institute of Stockholm and the Norwegian Radiumhospital in Oslo tested Tc-99m NC100692 in a study of 16 patients with suspicious mammograms and four patients with benign breast lesions 6 mm or larger. Imaging with the new agent detected 19 of 22 malignant lesions.

No serious adverse events were encountered with the new agent, though mild side effects occurred in five patients. Tc-99m sestamibi has been used in the past to support mammography, but its sensitivity never went beyond 50% for lesions smaller than 12 mm. Tc-99m NC100692 showed 100% sensitivity for lesions 10 mm or larger.

Related Videos
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Nina Kottler, MD, MS
Practical Insights on CT and MRI Neuroimaging and Reporting for Stroke Patients
Related Content
© 2024 MJH Life Sciences

All rights reserved.